Day: October 4, 2023

With trustworthy innovation at its core, Dayforce Co-Pilot extends Ceridian’s commitment to investing in AI capabilities TORONTO and MINNEAPOLIS, Oct. 04, 2023 (GLOBE NEWSWIRE) — Ceridian HCM Holding Inc. (NYSE: CDAY; TSX: CDAY), a global leader in human capital management (HCM) technology, today announced Dayforce Co-Pilot, a new suite of Dayforce features powered by artificial intelligence (AI). Dayforce Co-Pilot transforms work by automating repetitive tasks and serving as a hyper-personalized guide for employees. The announcement was made at INSIGHTS 2023, the company’s annual customer conference being held in Las Vegas and livestreamed online. Thousands of attendees are engaging in sessions and experiences centered on helping them drive success with “A Brand New Dayforce,” the conference’s theme. At the conference, the company...

TransUnion publishes comprehensive report on consumer experiences in the gig economy CHICAGO, Oct. 04, 2023 (GLOBE NEWSWIRE) — Nearly one in four (24%) Americans have been victimized by fraud or identity theft while using gig economy platforms, like delivery and ride-sharing apps. That is more than double the rate they experienced elsewhere, with only 10% reporting victimization outside gig platforms. These findings and more are part of a comprehensive study from TransUnion (NYSE: TRU) on the attitudes, behaviors and experiences of Americans participating in the gig economy as workers, consumers or both. The full findings are available in the 2023 U.S. Gig Economy Report. “The gig economy provides extraordinary convenience and flexibility for consumers and workers, and it all hinges on trust,” said Tracey Lazos, senior director...

Pre-clinical data for selective EP300 supports opportunity in solid and hematologic tumor types FHD-286, a potent, selective inhibitor of BRG1 and BRM, shows potential as a broad-based differentiation agent in both clinical and pre-clinical studies in multiple tumor typesCAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that new clinical and pre-clinical data for its BRG1/BRM inhibitor FHD-286, pre-clinical data for its selective EP300 program, and pre-clinical data for its BRD9 degrader FHD-609, will be presented at the AACR-NCI-EORTC International Conference. The conference will be held October 11–15, 2023, in Boston, Massachusetts. Foghorn...

Expanded analyses from robust Phase 1 INTERCEPT-AD trial exploring novel target engagement (dose-related), amyloid plaque reduction, and ARIA levels observed with ACU193 administration to be included in a symposium on Friday, October 27New data from additional exploratory analyses of ACU193 to also be presented in four virtual and in-person poster presentationsCHARLOTTESVILLE, Va. and INDIANAPOLIS, Oct. 04, 2023 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that it will present deeper insights and new exploratory findings from its Phase 1 INTERCEPT-AD trial evaluating ACU193, the first clinical-stage AβO-directed antibody...

HOLLYWOOD, Fla., Oct. 04, 2023 (GLOBE NEWSWIRE) — NV5 Global, Inc. (the “Company” or “NV5”) (Nasdaq: NVEE), a provider of technology, conformity assessment, and consulting solutions, today announced the winners of the 2023 NV5 National Society of Black Engineers (NSBE) scholarship awards. The ten scholarship awards are part of NV5’s five-year $275,000 commitment to NSBE. Scholarships were awarded to undergraduate and graduate students across the country studying a variety of disciplines, including civil, electrical, and mechanical engineering, geomatics, and computer science. “We are pleased to contribute to the development of talented engineers and technical professionals who will develop innovative and sustainable solutions to meet the nation’s growing need for essential infrastructure improvements,” said Dickerson Wright, PE,...

PRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release third quarter 2023 financial results on Wednesday, October 25, 2023, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the conference call will be available on the Investors section of the Company’s website following the call. About Integra LifeSciences At Integra...

A new, open marketplace to connect Dayforce capabilities across the partner, solution, and talent ecosystems TORONTO and MINNEAPOLIS, Oct. 04, 2023 (GLOBE NEWSWIRE) — Ceridian HCM Holding Inc. (NYSE: CDAY; TSX: CDAY), a global leader in human capital management (HCM) technology, today launched Dayforce Exchange, an open and connected marketplace that extends the Dayforce experience across applications, data, content, and the workforce. Comprised of three distinct yet unified pillars – Talent Exchange, Solution Exchange, and Partner Exchange – Dayforce Exchange extends the Dayforce platform’s unique HCM capabilities across internal and external networks, without extra navigation or login experiences. One security model, one sign-on, and the same single data model that Dayforce provides ensures reliability and compliance. The announcement...

Virtual Webinar to Take Place October 11, 2023 at 2:00pm ET PRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced that it will host a virtual KOL event titled GTX-104: a potential new treatment standard for rare and life-threatening aSAH on Wednesday, October 11, 2023 at 2:00pm ET. To register, click here. The event will feature W. Taylor Kimberly, MD, PhD (Massachusetts General Hospital) who will discuss the high unmet medical need and current treatment landscape for patients suffering from aSAH, a medical emergency in which bleeding occurs over the surface of the brain...

SEATTLE, Oct. 04, 2023 (GLOBE NEWSWIRE) — Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has entered into a definitive agreement for the purchase and sale of 890,208 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.37 per share of common stock (or pre-funded warrant in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 890,208 shares of common stock with an exercise price of $3.25 per share which will be immediately exercisable for a period of five and one-half years following...

AABBG ConvertAABBG ConvertLAS VEGAS, Oct. 04, 2023 (GLOBE NEWSWIRE) — Asia Broadband Inc. (OTC: AABB) (“AABB” or the “Company”) is asking all AABBG Token holders to CONVERT NOW to the new AABBG.ALGO Token by following the steps in their AABB Wallets per the convert graphic at the end of this notice. The new AABBG.ALGO Token will continue to be the same unique mine-to-token gold-backed cryptocurrency, but with upgraded benefits. The migration and conversion process from the Ethereum blockchain to the Algorand blockchain is currently underway. The Company has already successfully converted many AABBG token holders to the new AABBG.ALGO, allowing them access to the improved transaction efficiency, lower costs, and increased transparency on the Algorand blockchain. The Company’s decision to migrate to the Algorand blockchain...